57 results about "Increased risk" patented technology

The invention relates to an in vitro or ex vivo method for determining the risk of death for a subject infected with a respiratory virus, said method comprising the steps of measuring, in a biological sample from said subject, the expression level of the OAS2 gene, and comparing the expression level thus measured or a value derived from this amount to a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death for the subject when a sub-expression of the OAS2 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of OAS2 can be supplemented by a measurement of one or more additional genes such as C3ARI, CD177, ADGRE3, CIITA, IL-10, ILIR2, CD74, TDRD9 and combinations thereof. Kits for measuring the expression of OAS2 and optionally one or more additional genes are also disclosed.

Disclosed herein are classifier models, computer implemented systems, machine learning systems and methods thereof for classifying asymptomatic patients into a risk category for having or developing cancer and / or classifying a patient with an increased risk of having or developing cancer into an organ system-based malignancy class membership and / or into a specific cancer class membership.

The present disclosure describes methods and systems for predicting if a subject has an increased risk of having or developing one or more clinical outcomes, including prior to the detection of symptoms thereof and / or prior to onset of any detectable symptoms thereof. The present disclosure also describes a method of generating a model for predicting one or more clinical outcomes.

The present invention relates to a chromatin open site marker associated with the identification and early screening of high-risk populations for colorectal cancer and its application. The marker is rs10871066. Large-scale population data and biological functional experiments have confirmed that the rs10871066 site has functional regulatory activity, and individuals carrying the rs10871066[A] genotype are more likely to bind to the transcription factor FOXP1, while individuals carrying the rs10871066[G] genotype are more likely to bind to the transcription factor TCF7L2, thereby affecting the chromatin interaction between the region and the promoter of the target gene, promoting the expression levels of the target genes PIBF1 and KLF5, and thus promoting cancer cell proliferation, ultimately leading to an increased risk of colorectal cancer in individuals. By detecting the rs10871066 risk site in normal people, high-risk populations for colorectal cancer can be identified, assisting in the diagnosis of colorectal cancer patients.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

Methods and systems for identifying a patient at increased risk for development of a retinal condition employ visual field tests. A method of identifying a patient at increased risk for development of a retinal condition includes monitoring the patient via one or more visual field tests. Each of the visual field tests includes displaying stimuli for viewing by an eye of the patient and receiving indications of locations of the stimuli as perceived by the patient. A visual field test score for each of the visual field tests is determined based on the stimuli and the indications of locations of the stimuli as perceived by the patient. In response to at least one of the visual field test scores exceeding a screening threshold, the patient is identified as being at increased risk for development of the retinal condition.

The present invention includes methods and computer programs for use in the detection preeclampsia and / or determining an increased risk for preeclampsia in a pregnant female, the methods including identifying in a biosample obtained from the pregnant female cell-free DNA signals, including concentration, fetal fraction, and fragment size distribution. These methods provide for the identification of patients at risk of preeclampsia in the first trimester of pregnancy.

The invention provides methods for prognosing an increased risk of early onset preeclampsia (EOPE) in a pregnant subject before the disease onset. The methods comprises quantifying small extracellular vesicles that express pairs of biomarkers selected from CD10, CD63 and placental alkaline phosphatase (PLAP) in a sample obtained from the subject.

The invention provides application of a TTR tetramer in prognosis of a heart failure disease. The invention finds that serum TTR tetramer level reduction and NT-proBNP increase are possibly related to adverse clinical outcome events of heart failure patients, such as total cause death and cardiovascular death; after adjusting potential confounding factors, low TTR levels relate to all-cause death and an increase in all-cause rehospitalization risk. Therefore, the serum TTR tetramer and NT-proBNP can be used as potential biomarkers for prognosis of the heart failure disease and independent predictive factors for occurrence of adverse events. A good prediction index is provided for evaluating and improving prognosis of the heart failure disease, so that the survival rate of a patient is increased, the patient is fully benefited, and the application has huge potential and value in clinical application.

The inventors have identified new peptide biomarkers related to methylglyoxal (MGO)-induced glycation of plasma albumin, as well as the most abundant plasma apolipoproteins. Plasma concentrations of MGH-APOB1003184-3194, MGH-ALB219-225, CEL-APOA229-39 were higher in patients with type 2 diabetes (T2D). After follow-up, cases of major adverse cardiovascular events (MACE), cases of severe coronary artery disease (CAD) events, cases of cardiovascular (CV) deaths and cases of all-cause deaths were reported in The SURDIAGENE study (n = 1425). Increased plasma concentrations of MGH-APOB1003184-3194,MGH-ALB219- 225, CEL-APOA229-39 were significantly associated with an increased risk of developing MACE, CAD, CV death, and / or CV death. Thus the present invention refers to a method of predicting the risk of having or developing a cardiovascular event in a patient.

In one aspect, the disclosure provides a method for identifying whether a subject has or is at increased risk of developing a liver disease (e.g., non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatitis, cirrhosis, or cancer), comprising providing a cell-free deoxyribonucleic acid (cfDNA) sample derived from the subject, determining the cfDNA sample or a derivative thereof to determine a methylation pattern or methylation level of a DNA molecule of the cfDNA sample, processing the methylation pattern or methylation level using a trained machine learning (ML) algorithm to generate an output indicative of whether the cfDNA sample is positive for liver disease, and generating, based at least in part on the output, an electronic report indicating that the subject has a liver disease or an increased risk of developing a liver disease.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor:(Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.

The invention provides a risk prediction system and application of EB virus related hemophagocytic syndrome patients, five indexes UREA, DB, hscTnI, Ferr and PT are researched and developed to construct a scoring system, and if the score is greater than or equal to 3, the patient is prompted that the 28-day prognosis adverse risk is obviously increased (OR = 1.915). The model can provide a dynamic risk assessment tool for clinic and guide individualized treatment decisions.

Described herein are methods and systems for processing a biological sample of a subject to determine whether the subject has or is at an increased risk of developing a disease or disorder. Methods of the present disclosure may be performed using a trained machine learning algorithm to predict disease or risk of disease, identify disease, or monitor disease. Methods may be performed using a nuclear magnetic resonance (NMR) spectrum of a subject or a metabolome of the subject. Methods may predict, identify, or monitor diseases such as cancers, metabolic diseases or disorders, inflammatory diseases or disorders, or neurological diseases or disorders. Methods may be performed using a cloud computing system. Methods may provide a report to the subject indicating whether the subject has or is at an increased risk of developing a disease or disorder.

This utility model belongs to the field of yak disease prevention technology, specifically a yak disease prevention passageway. Addressing the problems of existing yak disease prevention passageways causing congestion and slow isolation during the transfer of suspected sick yaks, as well as limited spray range, incomplete disinfection, and increased risk of disease transmission, this invention proposes the following solution: It includes a main containment area and at least two sub-containment areas. A trapezoidal inspection passageway, wider at the top and narrower at the bottom, is provided between the main and sub-containment areas. Both ends of the inspection passageway connect to a self-propelled passageway. In this utility model, a reasonable passageway is constructed using trapezoidal frames to ensure orderly passage of yaks. Simultaneously, the drive component, in conjunction with the guardrail, allows for the rapid and safe transfer of sick yaks to the isolation area. A cylinder-driven fixing frame stabilizes and restrains the yaks, while the spray nozzles of disinfection pipes I and II achieve comprehensive disinfection. The coordinated operation of all components ensures efficient and continuous disease prevention, weighing, and isolation, reducing manpower and lowering the risk of disease transmission.

The invention discloses a syringic acid-based acute graft-versus-host disease prediction and use method, and belongs to the technical field of biological medicine.The syringic acid-based acute graft-versus-host disease prediction and use method comprises the steps that the occurrence and prognosis of aGVHD after transplantation are predicted by detecting the syringic acid level in an allo-HSCT patient, and reduction of the syringic acid level in the patient indicates increase of the aGVHD occurrence risk and poor prognosis; comprising the steps of giving an effective dose of syringic acid, inhibiting T cell activation and inflammatory factor secretion, relieving aGVHD symptoms, prolonging the survival time of an aGVHD model animal and improving target organ injury, and the diagnosis and prediction value of syringic acid in aGVHD occurrence and clinical prognosis is evaluated through a clinical sample. The application of syringic acid in prevention and treatment of aGVHD by inhibiting T cell function and inflammatory factor secretion is explored through in-vitro and animal experiment research, and the technical effects of helping clinicians to timely discover high-risk patients, formulate intervention measures in advance, improve prognosis of the patients and improve the treatment effect are achieved.

The invention provides methods of screening a subject for a proliferative disease risk factor which comprises detecting the presence or absence of target cells. The presence of target cells in the subject indicates the subject is at increased risk of developing a proliferative disease or recurrence of a previously treated proliferative disease and defines a new patient subgroup susceptible for treatment with selected anti-proliferative compounds. Methods of screening compounds for the treatment of proliferative diseases based on the presence of target cells and the expression of certain biomarkers by said target cells are also disclosed, along with appropriate compounds and their use in methods of treating such diseases.

There is provided a method of detecting an increase in risk of suffering from or developing renal cell carcinoma (RCC), comprising the steps of: a) determining a level of Enterocter asparaagiforms in a fecal sample of a human subject, b) determining a level of Enterocter asparaagiforms, c) determining a level of Enterocter asparaagiforms in a fecal sample of the human subject; b) comparing the determined level with a reference level; and c) determining that the human subject has an increased risk of suffering from or developing RCC if the determined level is above the reference level.

The invention relates to in situ methods for detecting the presence of misfolded proteins in samples (e.g. tissue samples). The invention also relates to the use of said methods in the detection of a proteinopathy or an increased risk thereof in a subject and to methods of determining the efficacy of therapeutic interventions.

The invention relates to an in vitro or ex vivo determination method for determining the risk of death of a patient infected by a respiratory virus, said method comprising the steps of measuring, in a biological sample from said patient, the expression level of the ADGRE3 gene, and of comparing the expression level thus measured or a value derived from this quantity with a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death of the patient when an underexpression of the ADGRE3 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of ADGRE3 can be supplemented by the measurement of one or more additional genes such as C3AR1, CD177, OAS2, CIITA, IL-10, IL1R2, CD74, TDRD9) and combinations thereof. The invention also relates to kits for measuring the expression of ADGRE3 and optionally of one or more additional genes.

The present invention relates to methods of reducing the risk of a major adverse cardiovascular event (MACE) in a subject comprising administering an RNAi agent, RNAi agents and pharmaceutical compositions for use in such methods, and the use of an RNAi agent for manufacturing a medicament for use in such methods. Provided herein are methods of particularly effectively preventing cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or emergency coronary blood supply reconstitution in a subject not undergoing a major atherosclerotic cardiovascular disease (ASCVD) event, particularly when the subject is at an increased risk of first MACE.

The present disclosure provides a method of detecting thromboxane B2 metabolites (TXB2-M) in a urine sample, including determining the amount of thromboxane B2 metabolites (TXB2-M) in the urine sample, adjusting or normalizing the amount of thromboxane B2 metabolites (TXB2-M) to creatinine (e.g., urine creatinine or creatinine level) in the urine sample (e.g., picogram (pg) of thromboxane B2 metabolites (TXB2-M) / milligram (mg) of creatinine), and adjusting or normalizing the creatinine (e.g., pg / mg) in the urine sample to renal function. The present disclosure further comprises methods of examining or determining mortality risk or hear failure risk in a subject, as well as methods of treating subjects (i) at increased risk for heart failure and / or (ii) at increased mortality risk of cardiovascular disease, heart failure, and / or stroke.

The inventors have identified new peptide biomarkers related to methylglyoxal (MGO)-induced glycation of plasma albumin, as well as the most abundant plasma apolipoproteins. Plasma concentrations of MGH-APOB1003184-3194, MGH-ALB219-225, CEL-APOA229-39 were higher in patients with type 2 diabetes (T2D). After follow-up, cases of major adverse cardiovascular events (MACE), cases of severe coronary artery disease (CAD) events, cases of cardiovascular (CV) deaths and cases of all-cause deaths were reported in The SURDIAGENE study (n = 1425). Increased plasma concentrations of MGH-APOB1003184-3194,MGH-ALB219- 225, CEL-APOA229-39 were significantly associated with an increased risk of developing MACE, CAD, CV death, and / or CV death. Thus the present invention refers to a method of predicting the risk of having or developing a cardiovascular event in a patient.

In certain embodiments, the present invention provides a panel of probes to detect biomarkers associated with ovarian cancer, wherein the probes hybridize to the biomarkers. Certain embodiments provide kits that comprise a panel of probes to detect biomarkers associated with ovarian cancer. In certain embodiments, the present invention provides a method of detecting the presence of biomarkers associated with an increased risk of ovarian cancer in a human subject. In certain embodiments, the present invention provides a method of treating a human subject for ovarian cancer.

The invention provides a compound characterized by formula (1): X1-Thr-Thr-Ala-Arg-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further provides an in vitro method for detecting protease activity in a subject's body fluid, comprising contacting the body fluid with the compound of the invention and detecting a signal, wherein the body fluid may comprise a hydrolytic enzyme derived from pancreatic cancer cells. Furthermore, the invention provides a kit comprising the compound of the invention and a measurement buffer. In addition, the invention provides the use of the compound, the in vitro method or the kit of the invention for the detection of pancreatic cancer, or for monitoring a subject that is suspected of having pancreatic cancer, has an increased risk of developing pancreatic cancer, or has had pancreatic cancer. The invention also provides the use of the compound of the invention in a method of treating pancreatic cancer, the method comprising carrying out the in vitro method for detecting protease activity in a subject's body fluid, and treating pancreatic cancer in a subject for which protease activity, has been detected.

A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM˜1 antibody to a nanoparticle. The composition may be used as an imaging agent and / or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

The present invention relates to the diagnosis of sepsis and / or septic shock and monitoring the extent thereof; the early assessment of the risk of developing sepsis and / or septic shock; the prediction or determination or monitoring of the need for a therapy or intervention in a subject. The present invention relates to a method which comprises determining the level of a biomarker selected from the group consisting of ADM-Gly, PAMP, MR-proADM and CT-proADM or a fragment of at least five amino acids thereof, or the total ADM, or the ratio of the level of said biomarker to the level of ADM-Nffz, in a sample of a subject, and wherein the level of said biomarker or said ratio is indicative of sepsis and / or septic shock or the extent of sepsis and / or septic shock, or is predictive of an increased risk of developing sepsis and / or septic shock, or is indicative of the need for a therapy or intervention in said subject for sepsis and / or septic shock.

The invention discloses a dangerous stratification model for hypertrophic cardiomyopathy and a preparation method and application thereof, and belongs to the technical field of biological medicine. The invention provides application of a reagent for detecting the expression level of PDCD5 protein. Researches find that expression increase of the serum PDCD5 protein is not only a risk factor of bad outcome of HCM patients, but also is independent of other clinical factors, and a survival curve of risk stratification according to the serum PDCD5 protein also has a good discrimination degree. The PDCD5 protein improves a risk stratification model of HCM established based on clinical factors. The non-synonymous variation of the VWCE, SPAG5, PDGFRB and PITX3 genes is independently related to the increase of the adverse outcome risk of HCM patients; on the basis of a score 2 established based on serum PDCD5 protein and clinical factors, the non-synonymous variation of the genes is combined, and the established multi-dimensional risk stratification model has good prediction efficiency on the adverse outcome of the HCM patient.

It is provided a sensor for measuring a biomarker or metabolite level such as glucose level in a fluid sample such as saliva comprising a sensing element comprising a redox reporter attached to at least one aptamer that binds to the biomarker or metabolite, and a solid surface where the sensing element is attached thereto, wherein upon binding of the biomarker or metabolite onto to the aptamer, the redox reporter undergoes a binding-induced change in electron transfer. Measuring the biomarker or metabolite level in the saliva of a patient will allow health monitoring in the patient such as increased risk of gum disease or diabetes in the patient.

The invention relates to methods for determining whether a subject has an increased risk of progression and / or recurrence of squamous cell carcinoma (SCC). In certain embodiments, the invention relates to determining the expression of Ambra-1 and p62 in one or more tissue samples obtained from the subject, wherein the tissue sample(s) comprise a primary tumour and tissue overlying the primary tumour and a decrease or loss in the expression of Ambra-1 and a decrease or loss in the expression of p62 in the tissue sample(s) compared to one or more reference level(s) is indicative of an increased risk of progression and / or recurrence of the tumour. The invention further relates to methods of treating subjects identified to be at increased risk of having progressive and / or recurring SCC.